公开(公告)号：US20080255121A1

公开(公告)日：2008-10-16

申请号：US11577894

申请日：2005-11-02

申请人： Shuzo Tagashira ,  Akihisa Fukushima

发明人： Shuzo Tagashira ,  Akihisa Fukushima

IPC分类号： A61K31/5377 ,  A61K31/42 ,  A61K31/519 ,  A61P37/00 ,  A61P3/10 ,  A61P7/00 ,  A61P29/00

CPC分类号： A61K31/519 ,  A61K31/18 ,  A61K31/42 ,  A61K31/426 ,  A61K31/5377 ,  A61K31/635 ,  A61K45/06 ,  A61K2300/00

摘要： It is intended to provide a combination drug for preventing and/or treating an autoimmune disease. More specifically speaking, a combination drug for preventing and/or treating an autoimmune disease which contains a CaMKII inhibitor and a disease-modifying antirheumatic drug; a medicinal composition, a commercial package, a kit, etc. for the combination; an enhancer for the effect of preventing and/or treating an autoimmune disease of a disease-modifying antirheumatic drug which contains a CaMKII inhibitor as the active ingredient; a method of screening a CaMKII inhibitor appropriately usable in combination, and so on.

摘要翻译： 旨在提供用于预防和/或治疗自身免疫性疾病的组合药物。 更具体地说，用于预防和/或治疗包含CaMKII抑制剂和疾病缓解性抗风湿药物的自身免疫性疾病的组合药物; 用于组合的药物组合物，商业包装，试剂盒等; 用于预防和/或治疗包含CaMKII抑制剂作为活性成分的疾病缓解性抗风湿药物的自身免疫性疾病的增强剂; 筛选适合组合使用的CaMKII抑制剂等的方法。

公开(公告)号：US20050158371A1

公开(公告)日：2005-07-21

申请号：US10921960

申请日：2004-08-20

申请人： Fumio Nishikado ,  Shuzo Tagashira ,  Koichi Saito ,  Toshiyuki Hosokawa

发明人： Fumio Nishikado ,  Shuzo Tagashira ,  Koichi Saito ,  Toshiyuki Hosokawa

IPC分类号： A61K9/70 ,  A61K31/277 ,  A61K31/42 ,  A61K31/5377 ,  A61K47/06 ,  A61K47/08 ,  A61K47/10

CPC分类号： A61K31/5377 ,  A61K9/0014 ,  A61K9/7023 ,  A61K31/277 ,  A61K31/42 ,  A61K47/06 ,  A61K47/08 ,  A61K47/10

摘要： The present invention relates to a transdermal administration preparation for external application such as ointment, cream and the like, which contains SMP-114 or leflunomide or a pharmaceutically acceptable acid addition salt thereof as an active ingredient. The present invention further relates to a pharmaceutical composition for transdermal administration which contains, a) as an active ingredient, N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide or an active motabolite thereof or a pharmaceutically acceptable salt thereof; and B)(1) a carrier for transdermal administration which contains a base for dissolution in a proportion of not less than 40 w/w %, or (2) a carrier for transdermal administration which contains a hydrophobic base for suspension having no polar group in a molecule in a proportion of not less than 70 w/w %. According to the present invention, a novel means of transdermal administration of SMP-114 or leflunomide or an active motabolite thereof or a pharmaceutically acceptable acid addition salt thereof can be provided.

摘要翻译： 本发明涉及含有SMP-114或来氟米特或其药学上可接受的酸加成盐作为活性成分的外用施用皮肤给药制剂，如软膏，霜剂等。 本发明还涉及用于透皮给药的药物组合物，其包含a）作为活性成分的N-（4-三氟甲基苯基）-5-甲基异恶唑-4-甲酰胺或其活性成分代谢物或其药学上可接受的盐; 和B）（1）经皮给药的载体，其含有不少于40w / w％的比例溶解的碱，或（2）用于透皮给药的载体，其含有不具有极性基团的悬浮的疏水性碱 在分子中的比例不小于70w / w％。 根据本发明，可以提供透皮给药SMP-114或来氟米特或其活性成
胶体或其药学上可接受的酸加成盐的新方法。